Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 11, 2019

Primary Completion Date

November 15, 2023

Study Completion Date

December 30, 2023

Conditions
OsteosarcomaPulmonary MetastasesApatinib
Interventions
DRUG

Apatinib

Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.

DRUG

GD regimen

"One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."

Trial Locations (1)

200025

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT03742193 - Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy | Biotech Hunter | Biotech Hunter